SNYR Synergy CHC: Company Value to Revenue Ratio

Public company logo of Synergy CHC Corp (SNYR)

Synergy CHC Corp (SNYR) is implementing RPA bots and robotic packaging, which is driving up the current EV/Sales multiple shown on this GURU.Markets chart, where the current value stands at 1037.55. The financial foundation relies on outsourcing production to third-party plants and generates revenue through retail sales of dietary supplements and natural cosmetics via online platforms and pharmacies.

Synergy CHC (SNYR): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 10/03/2026

Financial and market metric breakdowns for Synergy CHC Corporation (SNYR)

- price and consensus price forecast:
- money and cash flow information:
Fundamental valuation:Synergy CHC Corp. SNYR
Signature product of Synergy CHC Corp.

Synergy CHC Corp (SNYR) ensures the seamless delivery of health products through automated fulfillment, which supports high business margins. An analysis of the EV/Sales multiple chart allows for the correlation of the total enterprise value, excluding debt, with sales volume, revealing real market demand for assets and confirming the fundamental stability of current price levels.

Competitor analysis for Synergy CHC Corp

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio